Once-Daily Administration of Famotidine for Reflux Esophagitis

Abstract

S. Once-daily administration of famotidine for reflux esophagitis. Scand J Gastroenterol 1987, 22(suppl 134), 51-54 An open-labeled study of once-daily administration of 40 mg famotidine was conducted in 24 patients with endoscopically confirmed reflux esophagitis. The mean age of the patients was 62.8 years. Most had stage I or stage I1 esophagitis of 1 years' duration or less. After4,8,12, and 16 weeksof treatment, endoscopically documented healing was reported in 50%, 75%, 8296, and 83% of patients, respectively. Among specific endoscopic findings documented at the start of the study there was clearing of white exudate in 83% of patients, and redness cleared in 50% of patients after 16 weeks of treatment. Symptomatic improvement was observed in 73% of patients after 2 weeks, and this increased to 81% and 85% after 4 and 8 weeks of treatment, respectively. Painful symptoms cleared within 2 weeks in 68% of patients, and this increased to 77% after 8 weeks of once-daily therapy. Famotidine was well tolerated. Historically, reflux esophagitis has not responded satisfactorily to drug treatment. The reported symptomatic response and the response documented by endoscopy after therapy with 40 mg famotidine once daily at bedtime are encouraging. Further studies should be conducted to define the role of famotidine in the treatment of reflux esophagitis. Scand J Gastroenterol Downloaded from informahealthcare.com by McMaster University on 01/05/15 For personal use only. Switzerland, 1978, 135-142 enterology 1978, 74(2 part 2), 441-448 J Med 1985, 143, 616-621 1983, 24, 921-924 Scand J Gastroenterol Downloaded from informahealthcare.com by McMaster University on 01/05/15 For personal use only.

The effects of nizatidine on transient lower esophageal sphincter relaxations (TLESRs) and acid reflux in healthy subjects

“…A study carried out in Japan has found that nizatidine (NIZ) 150 mg bid, is more effective than other histamine H2 receptor agonists (H2RAs) in treating reflux esophagitis (RE), although the Correspondence to: Katsuhiko Iwakiri, M.D., Department of Medicine, Division of Gastroenterology, Nippon Medical School, Sendagi 1-1-5, Bunkyo-ku, Tokyo 113-8603, Japan Phone: +81-3-3822-2131 Fax: +81-3-5685-1793 e-mail: k-iwa@nms.ac.jp NIZ group did include more subjects with severe RE compared with the famotidine group (Sekiguchi et al, 1983;Nakano et al, 1984;Sekiguchi et al, 1989). In addition, it has been reported that maintenance therapy from NIZ has a significantly higher non-recurrence rate than that of famotidine in patients with RE (Hamamoto et al, 2005).…”

Rationale and efficacy of medical therapy for gastroesophageal reflux disease

“…Amongst the newer H2-blockers, famotidine is a drug capable of inducing a distinct dose-related reduction of acid exposure time [ 5 31 and has already shown a promising effect in the healing of endoscopic oesophagitis [54] : in this open study, healing rates at 4, 8, 12 and 1 6 weeks were 50, 75. 82 and 83%, respectively.…”

Medical Treatment of Gastroesophageal Reflux Disease: Options and Priorities

“…24 h reflux variables before and after treatment with famotidine or ranitidine heals 82% of patients with mild esophagitis ( 61). Famotidine 40 mg bid heals 48% of patients with moderate to severe esophagitis at six weeks compared with 18% with placebo (healing rates increasing to 69 and 29% at 12 weeks) ( 62 ).…”